Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring ...
Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to ...
The MHRA has granted marketing authorisation for Eylea ® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...
WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with ...
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and ...
Analysts covering EyePoint have refreshed their models, with bullish price targets now clustered in the US$29 to US$35 range. These revisions are being linked to more detailed valuation work on the ...
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be ...
Intraocular inflammation following high dose aflibercept may be more common in practice than phase 3 trials found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results